AstraZeneca’s Trixeo Aerosphere, already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has now been approved for use in the UK with an innovative, next-generation propellant with near-zero Global Warming Potential (GWP). This is the first medicine delivered by a pressurised metered-dose inhaler (pMDI) approved with a propellant that has 99.9% lower GWP than propellants used in currenatly available pMDIs. Trixeo with the next-generation propellant will have a low carbon footprint, comparable to inhaled medicines that do not require a propellant.
Omar Usmani, Professor of Respiratory Medicine at Imperial College London, said: “Pressurised metered-dose inhaled medicines are essential for millions of people living with respiratory diseases in the UK. The transition of Trixeo to the propellant with near-zero Global Warming Potential means that healthcare professionals can focus on optimising outcomes for their COPD patients based on clinical need, while also supporting climate goals. Clinicians and their patients shouldn’t feel that they have to choose between the most appropriate treatment and the planet.”
